EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells

Ravi Doddapaneni, Jason D Tucker iD, Pei J Lu, Qi L Lu

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26062661 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ravi Doddapaneni und 3 weiteren Autor:innen. Beteiligte Einrichtung: McColl-Lockwood Laboratory for Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, Atrium Health, Charlotte, NC 28203, USA. Hauptthemen laut MEDLINE: Naphthoquinones, Apoptosis, Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carolinas Muscular Dystrophy Research Endowment at the Atrium Health Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mortality rate of breast cancer remains high, despite remarkable advances in chemotherapy. Therefore, it is imperative to identify new treatment options. In the present study, we investigated whether the metabolite ribitol enhances the cytotoxic effect of shikonin against breast cancer in vitro. Here, we screened a panel of small molecules targeting energy metabolism against breast cancer. The results of the study revealed that ribitol enhances shikonin’s growth-inhibitory effects, with significant synergy. A significant (p < 0.01) increase in the percentage (56%) of apoptotic cells was detected in the combined treatment group, compared to shikonin single-treatment group (38%), respectively. The combined ribitol and shikonin treatment led to significant arrest of cell proliferation (40%) (p < 0.01) compared to untreated cells, as well as the induction of apoptosis. This was associated with upregulation of p53 (p < 0.05) and downregulation of c-Myc (p < 0.01), Bcl-xL (p < 0.001), and Mcl-1 (p < 0.05). Metabolomic analysis supports the premise that inhibition of the Warburg effect is involved in shikonin-induced cell death, which is likely further enhanced by dysregulation of glycolysis and the tricarboxylic acid (TCA) cycle, afflicted by ribitol treatment. In conclusion, the present study demonstrates that the metabolite ribitol selectively enhances the cytotoxic effect mediated by shikonin against breast cancer in vitro.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaphthoquinonesApoptosisBreast NeoplasmsHumansFemaleDrug SynergismCell ProliferationCell Line, TumorMCF-7 CellsGene Expression Regulation, NeoplasticAntineoplastic Agents

Stichwörter der Autor:innen

breast cancerchemotherapydrug synergymetabolomicsribitolshikonin

Substanzen

shikoninNaphthoquinonesAntineoplastic Agents

Autor:innen und Institutionen

  • McColl-Lockwood Laboratory for Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, Atrium Health, Charlotte, NC 28203, USA.

ORCID-Profile: Jason D Tucker

Förderung

  • Carolinas Muscular Dystrophy Research Endowment at the Atrium Health Foundation

Zitieren

APA

Doddapaneni, R., Tucker, J. D., Lu, P. J., & Lu, Q. L. (2025). Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26062661

Vancouver

Doddapaneni R, Tucker JD, Lu PJ, Lu QL. Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26062661

BibTeX
@article{Doddapaneni2025,
  author = {Doddapaneni, Ravi and Tucker, Jason D and Lu, Pei J and Lu, Qi L},
  title = {Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26062661}
}
Kostenlos starten →